LILRB4 and acute myeloid leukemia: This work characterizes a novel mechanism of FcγR-mediated antigenic modulation of LILRB4 in monocytic AML and will aid the development of a new generation of therapeutic antibodies optimized to take advantage of this unique biology in myeloid malignancy while maintaining Fc-mediated immune effector functions such as ADCC and ADCP.